Developments Xeris Pharma posts positive topline data from Phase 2 T1D study Xeris Pharmaceuticals (NASDAQ:XERS) reported positive topline results from its Phase 2 study of XP-3924, a pramlintide-insulin co-formulation, in adults with Type 1 diabetes (T1D). The trial enrolled 18 adults with T1D... June 18, 2020